Abilify Review Shows FDA Debate Over QTc Methods Of Analysis
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
FDA’s review of Bristol-Myers Squibb/Otsuka’s atypical antipsychotic Abilify suggests that the method of analysis used to detect QT prolongation is key to the results.
You may also be interested in...
Abilify Comparative Safety Claims Require Least Favorable Dose Comparison
Comparative safety claims for Bristol-Myers Squibb/Otsuka’s atypical antipsychotic Abilify would require studies comparing the highest dose of aripiprazole to the lowest dose of the comparator or a more complicated multi-dose comparative trial, FDA review documents show.
Abilify Comparative Safety Claims Require Least Favorable Dose Comparison
Comparative safety claims for Bristol-Myers Squibb/Otsuka’s atypical antipsychotic Abilify would require studies comparing the highest dose of aripiprazole to the lowest dose of the comparator or a more complicated multi-dose comparative trial, FDA review documents show.
Lilly Avoids Strattera Risk Management Program; QTc Key Concern In Review
Lilly’s response to an "approvable" letter for Strattera allowed the company to avoid a label requirement to test for poor metabolizers of the drug, as well as a related warning on QTc prolongation, review documents indicate.